[ad_1]
Amsterdam, Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the appointment of Julia Strandberg as Chief Business Officer of its Connected Care business, effective April 24, 2023. Ms. Strandberg will be a member of Phillips. The Executive Committee reports to Philips CEO Roy Jacobs. Effective April 1, 2023, Philips’ connected care businesses will include the monitoring, sleep and respiratory care, and enterprise informatics businesses.
Ms. Strandberg (American, 1974) joined Philips from Peer Therapeutics, where she served as CEO of the business group that built, launched and grew its digital prescription therapeutics offering. Previously, Ms. Strandberg led a healthcare business consulting firm focused on driving client growth, and previously led Medtronic’s global health informatics and monitoring business, and was global marketing leader for patient monitoring in Covidien’s Respiratory & Monitoring group. Acquired by Medtronic. Ms. Strandberg began her career at 3M and held various positions within the company.
“On behalf of the Philips Executive Committee, I am delighted to announce that Julia Strandberg will join Philips as the new Chief Business Leader of the Connected Care businesses and a member of the Executive Committee,” said Roy Jacobs, CEO of Royal Philips. “Julia brings deep, multidisciplinary expertise, including informatics and monitoring, to Philips. With a focus on improving the healthcare experience for patients and providers across all care settings, Julia understands how to deliver in the global healthcare ecosystem and adds extensive experience in developing and commercializing medical technologies.
Ms. Strandberg replaces Dan Leonard, who took on the interim role of chief business officer of ConnectedCare Advertising when Roy Jacobs became CEO in October 2022.
Philips’ strong brand and compelling purpose attract and attract talent, and the company continues to strengthen the organization with new health technology talent, including experienced leaders with deep knowledge. Ms. Strandberg’s appointment to the Philips Executive Committee follows the promotion of Wim Aplo as Philips’ Chief Operating Officer and Steve C. de Baca as Philips’ Chief Patient Safety and Quality Officer, as well as Jeff DiLulon. Philips is the North American market leader.
More information about the Phillips Executive Committee can be found here. over here.
For more information please contact:
Ben Zwirs
Philips Global Press Office
Phone: +31 615213446
Email: ben.zwirs@philips.com
Derya Guzel
Phillips Investor Relations
Phone: +31 20 59 77055
Email: derya.guzel@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centered innovation delivers advanced technology and deep clinical and consumer insights into personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and at home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as personal health. Philips generates 2022 sales of 17.8 billion euros and employs approximately 77,000 sales and service personnel in more than 100 countries. News about Philips is available at www.philips.com/newscenter.
Forward-looking statements
This release contains certain forward-looking statements regarding the financial condition, operations and business results of Philips and Philips’ plans and objectives. Examples of forward-looking statements include statements about the strategy, sales growth estimates, future EBTA, future developments in the Philips Organics business and the completion of acquisitions and divestitures. By their nature, these statements involve risk and uncertainty because they relate to future events and conditions and there are many factors that could cause actual results and developments to differ from those expressed or implied by these statements.
Appendix
[ad_2]
Source link
